In Reply.

COI Statement

Financial Disclosure Jennifer L. Goralski disclosed that she received payment from Vertex Pharmaceuticals. Asha Talati did not report any potential conflicts of interest.

References:

• Goralski JL, Talati AN, Hardisty EE, Vora NL. Pregnancy in people with cystic fibrosis treated with highly effective modulator Therapy. Obstet Gynecol 2025;145:47–54. doi: 10.1097/aog.0000000000005732
• Kazmerski TM, Stransky OM, Lee M, Prangley KA, Jain R, Georgiopoulos AM, et al. Assessing the health impacts of parenthood on people with cystic fibrosis: the HOPeCF prospective cohort protocol. BMJ Open Respir Res 2024;11:e002383. doi: 10.1136/bmjresp-2024-002383
• Jain R, Peng G, Lee M, Keller A, Cosmich S, Reddy S, et al. Impact of cystic fibrosis transmembrane conductance regulator modulators on maternal outcomes during and after pregnancy. Chest 2024;167:348–61. doi: 10.1016/j.chest.2024.09.019
• Patel P, Yeley J, Brown C, Wesson M, Lesko BG, Slaven JE, et al. Immunoreactive trypsinogen in infants born to women with cystic fibrosis taking elexacaftor-tezacaftor-ivacaftor. Int J Neonatal Screen 2023;9:10. doi: 10.3390/ijns9010010